EGFR is one of the most important targets of antitumor therapy, and EGFR antagonists may eventually play an indispensable clinical role not only in the treatment of malignant tumors but also in the treatment of pain, especially cancer pain, which is resistant to opioid treatment. The gene discussed is EGFR; the disease is cancer.